RECORDATI |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51 EUR | -3.04% |
|
+4.21% | +4.44% |
| 02:21pm | CVC Said Mulling Options for Majority Stake in Recordati | MT |
| 12:06pm | Mib cautiously active; STM uptrend continues. | AN |
| Sales 2024 * | 2.3B 2.46B | Sales 2025 * | 2.44B 2.6B | Capitalization | 10.83B 11.57B |
|---|---|---|---|---|---|
| Net income 2024 * | 477M 510M | Net income 2025 * | 523M 559M | EV / Sales 2024 * | 5.28 x |
| Net Debt 2024 * | 1.31B 1.4B | Net Debt 2025 * | 1.08B 1.15B | EV / Sales 2025 * | 4.88 x |
| P/E ratio 2024 * |
23.5
x | P/E ratio 2025 * |
21.1
x | Employees | 4,455 |
| Yield 2024 * |
2.67% | Yield 2025 * |
2.94% | Free-Float | 46.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on Recordati
More press releases
More news
| 1 day | -3.04% | ||
| 1 week | +4.21% | ||
| Current month | -0.47% | ||
| 1 month | -1.92% | ||
| 3 months | +2.12% | ||
| 6 months | +14.94% | ||
| Current year | +4.44% |
1 week
48.66
53.40
1 month
48.5453.40
Current year
47.2953.40
1 year
40.0053.40
3 years
34.5257.90
5 years
28.2657.90
10 years
11.1257.90
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Koremans
CEO | Chief Executive Officer | 61 | 21-11-30 |
Luigi la Corte
DFI | Director of Finance/CFO | 54 | 19-10-31 |
Andrea Recordati
CHM | Chairman | 52 | 98-04-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cathrin Petty
BRD | Director/Board Member | 50 | 18-06-11 |
Giampiero Mazza
BRD | Director/Board Member | 54 | 18-06-11 |
Robert Koremans
CEO | Chief Executive Officer | 61 | 21-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.52% | 5 M€ | +12.55% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 51 | -3.04% | 194 905 |
| 24-04-23 | 52.6 | +2.94% | 390,244 |
| 24-04-22 | 51.1 | +2.49% | 474,728 |
| 24-04-19 | 49.86 | +0.24% | 252,235 |
| 24-04-18 | 49.74 | +1.63% | 226,309 |
Real-time Borsa Italiana, April 24, 2024 at 08:38 am EDT
More quotes
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.;
- medicines for rare diseases (32.1%).
Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
52.6
EUR
Average target price
51.64
EUR
Spread / Average Target
-1.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.44% | 11.58B | |
| +27.92% | 672B | |
| +26.83% | 570B | |
| -4.59% | 360B | |
| +16.38% | 321B | |
| +9.39% | 300B | |
| +7.43% | 217B | |
| +6.37% | 199B | |
| -8.92% | 204B | |
| -8.58% | 149B |
- Stock Market
- Equities
- REC Stock
